|
[1]H. Paganetti et al., "Relative biological effectiveness (RBE) values for proton beam therapy," INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 53, no. 2, pp. 407-421, JUN 1 2002, Art no. Pii s0360-3016(02)02754-2, doi: 10.1016/S0360-3016(02)02754-2. [2]I. A. E. Agency, Relative biological effectiveness in ion beam therapy. International Atomic Energy Agency, 2008. [3]W. Newhauser, "International commission on radiation units and measurements report 78: Prescribing, recording and reporting proton-beam therapy," ed: Oxford University Press, 2009. [4]H. Paganetti, "Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer," PHYSICS IN MEDICINE AND BIOLOGY, vol. 59, no. 22, pp. R419-R472, NOV 21 2014, doi: 10.1088/0031-9155/59/22/R419. [5]B. Jones, "Why RBE must be a variable and not a constant in proton therapy," BRITISH JOURNAL OF RADIOLOGY, vol. 89, no. 1063, 2016, Art no. 20160116, doi: 10.1259/bjr.20160116. [6]M. Belli, A. Campa, and I. Ermolli, "A semi-empirical approach to the evaluation of the relative biological effectiveness of therapeutic proton beams: The methodological framework," RADIATION RESEARCH, vol. 148, no. 6, pp. 592-598, DEC 1997, doi: 10.2307/3579735. [7]J. J. Wilkens and U. Oelfke, "A phenomenological model for the relative biological effectiveness in therapeutic proton beams," PHYSICS IN MEDICINE AND BIOLOGY, vol. 49, no. 13, pp. 2811-2825, JUL 7 2004, Art no. Pii s0031-9155(04)74984-2, doi: 10.1088/0031-9155/49/13/004. [8]N. Tilly et al., "The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer," PHYSICS IN MEDICINE AND BIOLOGY, vol. 50, no. 12, pp. 2765-2777, JUN 21 2005, doi: 10.1088/0031-9155/50/12/003. [9]B. Jones, "Towards Achieving the Full Clinical Potential of Proton Therapy by Inclusion of LET and RBE Models," CANCERS, vol. 7, no. 1, pp. 460-480, MAR 2015, doi: 10.3390/cancers7010460. [10]F. Tommasino and M. Durante, "Proton Radiobiology," CANCERS, vol. 7, no. 1, pp. 353-381, MAR 2015, doi: 10.3390/cancers7010353. [11]G. Giovannini et al., "Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios," RADIATION ONCOLOGY, vol. 11, MAY 17 2016, Art no. 68, doi: 10.1186/s13014-016-0642-6. [12]M. Marteinsdottir and H. Paganetti, "Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer," PHYSICS IN MEDICINE AND BIOLOGY, vol. 64, no. 11, JUN 2019, Art no. 115027, doi: 10.1088/1361-6560/ab2144. [13]B. S. Sorensen et al., "Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?," RADIOTHERAPY AND ONCOLOGY, vol. 163, pp. 177-184, OCT 2021, doi: 10.1016/j.radonc.2021.08.016. [14]E. Rorvik et al., "Exploration and application of phenomenological RBE models for proton therapy," PHYSICS IN MEDICINE AND BIOLOGY, vol. 63, no. 18, SEP 2018, Art no. 185013, doi: 10.1088/1361-6560/aad9db. [15]Y. Lin, M. Yang, C. Wan, J. H. Wang, and Y. H. Song, "A Multi-Model Combination Approach for Probabilistic Wind Power Forecasting," IEEE TRANSACTIONS ON SUSTAINABLE ENERGY, vol. 10, no. 1, pp. 226-237, JAN 2019, doi: 10.1109/TSTE.2018.2831238. [16]Z. H. Zhao, X. Y. Zhang, G. H. Zou, A. T. K. Wan, and G. K. F. Tso, "Model averaging for estimating treatment effects," ANNALS OF THE INSTITUTE OF STATISTICAL MATHEMATICS, 2023 JUN 30 2023, doi: 10.1007/s10463-023-00876-4. [17]E. Pagliano and J. Meija, "Calibration model averaging in chemical analysis: a case study for the method of standard additions," METROLOGIA, vol. 60, no. 3, JUN 1 2023, Art no. 035003, doi: 10.1088/1681-7575/accd75. [18]E. Dixon, M. Hameed, F. Sutherland, D. J. Cook, and C. Doig, "Evaluating meta-analyses in the general surgical literature: a critical appraisal," Annals of surgery, vol. 241, no. 3, p. 450, 2005. [19]D. Moher, J. Tetzlaff, A. C. Tricco, M. Sampson, and D. G. Altman, "Epidemiology and reporting characteristics of systematic reviews," PLoS medicine, vol. 4, no. 3, p. e78, 2007. [20]M. Dong et al., "Efficacy and safety of carbon ion radiotherapy for bone sarcomas: a systematic review and meta-analysis," RADIATION ONCOLOGY, vol. 17, no. 1, OCT 25 2022, Art no. 172, doi: 10.1186/s13014-022-02089-0. [21]A. Iannalfi, G. Riva, L. Ciccone, and E. Orlandi, "The role of particle radiotherapy in the treatment of skull base tumors," FRONTIERS IN ONCOLOGY, vol. 13, JUN 7 2023, Art no. 1161752, doi: 10.3389/fonc.2023.1161752. [22]W. H. Cao et al., "Intensity modulated proton arc therapy via geometry-based energy selection for ependymoma," JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2023 MAR 13 2023, doi: 10.1002/acm2.13954. [23]K. Kasamatsu et al., "Hyperfractionated intensity-modulated proton therapy for pharyngeal cancer with variable relative biological effectiveness: A simulation study," MEDICAL PHYSICS, vol. 49, no. 12, pp. 7815-7825, DEC 2022, doi: 10.1002/mp.16064. [24]S. J. McMahon, "Proton RBE models: commonalities and differences," PHYSICS IN MEDICINE AND BIOLOGY, vol. 66, no. 4, FEB 21 2021, Art no. 04nt02, doi: 10.1088/1361-6560/abda98. [25]T. J. Dahle et al., "The FLUKA Monte Carlo code coupled with an OER model for biologically weighted dose calculations in proton therapy of hypoxic tumors," PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, vol. 76, pp. 166-172, AUG 2020, doi: 10.1016/j.ejmp.2020.07.003. [26]S. H. Yoo et al., "Study on Treatment Planning for the Prostate in Proton Therapy with Oxygen Enhancement Ratio Effect," JOURNAL OF THE KOREAN PHYSICAL SOCIETY, vol. 77, no. 7, pp. 613-623, OCT 2020, doi: 10.3938/jkps.77.613. [27]G. Garrido-Hernandez, H. Henjum, M. K. Hoiskar, T. J. Dahle, K. R. Redalen, and K. S. Ytre-Hauge, "Hypoxia adapted relative biological effectiveness models for proton therapy: a simulation study," BIOMEDICAL PHYSICS & ENGINEERING EXPRESS, vol. 8, no. 6, NOV 1 2022, Art no. 065026, doi: 10.1088/2057-1976/ac9b5d. [28]D. Sanchez-Parcerisa, M. Lopez-Aguirre, A. D. Llerena, and J. M. Udias, "MultiRBE: Treatment planning for protons with selective radiobiological effectiveness," MEDICAL PHYSICS, vol. 46, no. 9, pp. 4276-4284, SEP 2019, doi: 10.1002/mp.13718. [29]S. Huang et al., "Validation and application of a fast Monte Carlo algorithm for assessing the clinical impact of approximations in analytical dose calculations for pencil beam scanning proton therapy," MEDICAL PHYSICS, vol. 45, no. 12, pp. 5631-5642, DEC 2018, doi: 10.1002/mp.13231. [30]D. Wagenaar et al., "Validation of linear energy transfer computed in a Monte Carlo dose engine of a commercial treatment planning system," PHYSICS IN MEDICINE AND BIOLOGY, vol. 65, no. 2, JAN 2020, Art no. 025006, doi: 10.1088/1361-6560/ab5e97. [31]W. Deng et al., "Technical Note: Integrating an open source Monte Carlo code "MCsquare" for clinical use in intensity-modulated proton therapy," MEDICAL PHYSICS, vol. 47, no. 6, pp. 2558-2574, JUN 2020, doi: 10.1002/mp.14125. [32]F. Kalholm, L. Grzanka, E. Traneus, and N. Bassler, "A systematic review on the usage of averaged LET in radiation biology for particle therapy," RADIOTHERAPY AND ONCOLOGY, vol. 161, pp. 211-221, AUG 2021, doi: 10.1016/j.radonc.2021.04.007. [33]F. Romano et al., "A Monte Carlo study for the calculation of the average linear energy transfer (LET) distributions for a clinical proton beam line and a radiobiological carbon ion beam line," PHYSICS IN MEDICINE AND BIOLOGY, vol. 59, no. 12, pp. 2863-2882, JUN 21 2014, doi: 10.1088/0031-9155/59/12/2863. [34]M. A. Cortes-Giraldo and A. Carabe, "A critical study of different Monte Carlo scoring methods of dose average linear-energy-transfer maps calculated in voxelized geometries irradiated with clinical proton beams," PHYSICS IN MEDICINE AND BIOLOGY, vol. 60, no. 7, pp. 2645-2669, APR 7 2015, doi: 10.1088/0031-9155/60/7/2645. [35]F. Guan et al., "Analysis of the track- and dose-averaged LET and LET spectra in proton therapy using the GEANT4 Monte Carlo code," MEDICAL PHYSICS, vol. 42, no. 11, pp. 6234-6247, NOV 2015, doi: 10.1118/1.4932217. [36]M. G. Sezgin and H. Bektas, "The effect of decision support systems on pain in patients with cancer: A systematic review and meta-analysis of randomized controlled trials," JOURNAL OF NURSING SCHOLARSHIP, vol. 54, no. 5, pp. 578-588, SEP 2022, doi: 10.1111/jnu.12769. [37]T. H. Barker et al., "Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process," JBI EVIDENCE SYNTHESIS, vol. 21, no. 3, pp. 478-493, MAR 2023, doi: 10.11124/JBIES-22-00125. [38]D. B. Belli, P. Calzolari, F. Cera, R. Cherubini, M. Dalla Vecchia, M. Durante, S. Favaretto, G. Gialanella, G. Grossi, M, "Inactivation of human normal and tumour cells irradiated with low energy protons," International journal of radiation biology, vol. 76, no. 6, pp. 831-839, 2000. [39]M. C. Frese, J. J. Wilkens, P. E. Huber, A. D. Jensen, U. Oelfke, and Z. Taheri-Kadkhoda, "APPLICATION OF CONSTANT VS. VARIABLE RELATIVE BIOLOGICAL EFFECTIVENESS IN TREATMENT PLANNING OF INTENSITY-MODULATED PROTON THERAPY," INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 79, no. 1, pp. 80-88, JAN 1 2011, doi: 10.1016/j.ijrobp.2009.10.022. [40]A. Carabe-Fernandez, R. G. Dale, and B. Jones, "The incorporation of the concept of minimum RBE (RBEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments," INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, vol. 83, no. 1, pp. 27-39, JAN 2007, doi: 10.1080/09553000601087176. [41]M. Wedenberg, B. K. Lind, and B. Hardemark, "A model for the relative biological effectiveness of protons: The tissue specific parameter alpha/beta of photons is a predictor for the sensitivity to LET changes," ACTA ONCOLOGICA, vol. 52, no. 3, pp. 580-588, APR 2013, doi: 10.3109/0284186X.2012.705892. [42]A. L. McNamara, J. Schuemann, and H. Paganetti, "A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data," PHYSICS IN MEDICINE AND BIOLOGY, vol. 60, no. 21, pp. 8399-8416, NOV 7 2015, doi: 10.1088/0031-9155/60/21/8399. [43]W. Y. C. Koh et al., "Quantifying Systematic RBE-Weighted Dose Uncertainty Arising from Multiple Variable RBE Models in Organ at Risk," ADVANCES IN RADIATION ONCOLOGY, vol. 7, no. 2, MAR-APR 2022, Art no. 100844, doi: 10.1016/j.adro.2021.100844. [44]C. Pinter, A. Lasso, A. Wang, D. Jaffray, and G. Fichtinger, "SlicerRT: Radiation therapy research toolkit for 3D Slicer," MEDICAL PHYSICS, vol. 39, no. 10, pp. 6332-6338, OCT 2012, doi: 10.1118/1.4754659. [45]M. Hadi et al., "Utilizing 3D Slicer to incorporate tomographic images into GATE Monte Carlo simulation for personalized dosimetry in yttrium-90 radioembolization," MEDICAL PHYSICS, vol. 49, no. 12, pp. 7742-7753, DEC 2022, doi: 10.1002/mp.15980. [46]D. V. Parums, "Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines," MEDICAL SCIENCE MONITOR, vol. 27, AUG 23 2021, Art no. e934475, doi: 10.12659/MSM.934475. [47]H. Paganetti, "Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in alpha/beta," ACTA ONCOLOGICA, vol. 56, no. 11, pp. 1379-1386, 2017, doi: 10.1080/0284186X.2017.1371325. [48]D. Giantsoudi, J. Adams, S. M. MacDonald, and H. Paganetti, "Proton Treatment Techniques for Posterior Fossa Tumors: Consequences for Linear Energy Transfer and Dose-Volume Parameters for the Brainstem and Organs at Risk," INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 97, no. 2, pp. 401-410, FEB 1 2017, doi: 10.1016/j.ijrobp.2016.09.042. [49]D. Giantsoudi, J. Adams, S. MacDonald, and H. Paganetti, "Can differences in linear energy transfer and thus relative biological effectiveness compromise the dosimetric advantage of intensity-modulated proton therapy as compared to passively scattered proton therapy?," ACTA ONCOLOGICA, vol. 57, no. 9, pp. 1259-1264, 2018, doi: 10.1080/0284186X.2018.1468090. [50]A. Gutierrez et al., "The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton plans relative to VMAT," ACTA ONCOLOGICA, vol. 58, no. 12, pp. 1765-1774, DEC 2 2019, doi: 10.1080/0284186X.2019.1653496. [51]L. F. Fjaera et al., "Spatial Agreement of Brainstem Dose Distributions Depending on Biological Model in Proton Therapy for Pediatric Brain Tumors," ADVANCES IN RADIATION ONCOLOGY, vol. 6, no. 1, JAN-FEB 2021, Art no. 100551, doi: 10.1016/j.adro.2020.08.008. [52]H. J. Shang et al., "Impact of Multiple Beams on Plan Quality, Linear Energy Transfer Distribution, and Plan Robustness of Intensity Modulated Proton Therapy for Lung Cancer," ACS SENSORS, vol. 6, no. 2, pp. 408-417, FEB 26 2021, doi: 10.1021/acssensors.0c01879. [53]T. Henry and J. Oden, "Interlaced proton grid therapy - Linear energy transfer and relative biological effectiveness distributions," PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, vol. 56, pp. 81-89, DEC 2018, doi: 10.1016/j.ejmp.2018.10.025. [54]H. Ishikawa et al., "A Japanese registry study and systematic review of particle therapy for renal cell carcinoma," JOURNAL OF RADIATION RESEARCH, 2023 APR 12 2023, Art no. rrad010, doi: 10.1093/jrr/rrad010. [55]E. Cacao and F. A. Cucinotta, "Meta-analysis of Cognitive Performance by Novel Object Recognition after Proton and Heavy Ion Exposures," RADIATION RESEARCH, vol. 192, no. 5, pp. 463-472, NOV 2019, doi: 10.1667/RR15419.1. [56]B. Rombi et al., "PROTON RADIOTHERAPY FOR PEDIATRIC EWING'S SARCOMA: INITIAL CLINICAL OUTCOMES," INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 82, no. 3, pp. 1142-1148, MAR 1 2012, doi: 10.1016/j.ijrobp.2011.03.038. [57]S. Volpe et al., "Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis," CANCER TREATMENT REVIEWS, vol. 110, NOV 2022, Art no. 102464, doi: 10.1016/j.ctrv.2022.102464. [58]E. Rorvik, S. Thornqvist, C. H. Stokkevag, T. J. Dahle, L. F. Fjaera, and K. S. Ytre-Hauge, "A phenomenological biological dose model for proton therapy based on linear energy transfer spectra," MEDICAL PHYSICS, vol. 44, no. 6, pp. 2586-2594, JUN 2017, doi: 10.1002/mp.12216. [59]C. B. Liu et al., "RBE-weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy," JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, vol. 23, no. 4, APR 2022, doi: 10.1002/acm2.13527. [60]P. Yepes et al., "Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy," ADVANCES IN RADIATION ONCOLOGY, vol. 4, no. 1, pp. 156-167, JAN-MAR 2019, doi: 10.1016/j.adro.2018.08.020. [61]J. M. Søbstad, "Monte Carlo based comparison of constant vs. variable RBE for proton therapy patients," MASTER MASTER THESIS IN MEDICAL PHYSICS, UNIVERSITY OF BERGEN, 2017.
|